Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator (SERM) exhibiting a fixed ring structure analogous to raloxifene. This compound demonstrates potent antiestrogenic effects on breast cancer and endometrium while displaying minimal side effects. Additionally, Arzoxifene elicits favorable estrogenic effects on bone health and lipid profile.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 970.00 |
Description | Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator (SERM) exhibiting a fixed ring structure analogous to raloxifene. This compound demonstrates potent antiestrogenic effects on breast cancer and endometrium while displaying minimal side effects. Additionally, Arzoxifene elicits favorable estrogenic effects on bone health and lipid profile. |
In vitro | Arzoxifene decreases the expression of estrogen receptors in endometrial cancer cell lines (ECC-1)[1]. |
In vivo | Arzoxifene effectively suppresses the growth of MCF-7 breast cancer xenografts in oophorectomized athymic mice and has been documented to halt body weight gain in oophorectomized rats [1]. |
Synonyms | LY353381, Arzoxifene, SERMIII |
Molecular Weight | 475.6 |
Formula | C28H29NO4S |
CAS No. | 182133-25-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Arzoxifene 182133-25-1 LY353381 LY-353381 LY 353381 SERMIII inhibitor inhibit